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Introduction
Multiple myeloma is a clonal, multistep, plasma cell malignancy (1, 2) . Multiple myeloma often begins with premalignant monoclonal gammopathy of undetermined significance (MGUS), followed by asymptomatic smoldering multiple myeloma (SMM) and active multiple myeloma (3) . As the disease advances, the immune system demonstrates progressive impairment (4, 5) .
The introduction of immunomodulatory drugs (IMiD), proteasome inhibitors (PI), and monoclonal antibodies (mAb) has improved patient outcomes, partially exerting anti-multiple myeloma activity through immunomodulation (6) . Nevertheless, multiple myeloma remains incurable, becoming more aggressive with poor outcomes when treatment refractoriness occurs (7) . The role of T-cell dysfunction in multiple myeloma and the success of T-cell-directed therapy in other malignancies warrant investigation of treatments enhancing T-cell anti-multiple myeloma activity (8) . This review discusses the role of T cells and T-cell-directed therapies across the multiple myeloma disease continuum.
Evolution of T-cell Immunity in Multiple Myeloma Disease Progression
Reduced T-cell immunity has been associated with multiple myeloma disease progression ( Fig. 1 ). However, even in patients with MGUS, increased levels of immunosuppressive regulatory T cells (Treg; ref. 9 ) and T-cell exhaustion (10) have been reported. An immune profiling study found that T cells from patients with SMM had an aberrant phenotypic profile, including reduced expression of activation markers, compared with those from age-matched healthy controls (5) . Early changes in the T-cell population, including the presence of antigen-specific immunity and an enrichment of bone marrow (BM) stem-like/resident memory (TRM) T cells may prevent attrition of protective immunity and subsequent disease progression (10) (11) (12) .
Progression to multiple myeloma has been associated with further immune dysfunction due to an altered T-cell repertoire, with features of terminally differentiated T cells and loss of antigen-specific T-cell function (Fig. 1) . In multiple myeloma, loss of stem-like/TRM T cells (10) as well as increases in Tregs (9, 13) and proinflammatory Th17 cells (9, 14, 15) have been observed. These changes may have implications for T-cell-directed therapy. For example, loss of stemlike/TRM T cells may affect the durability of T-cell redirection or responsiveness to immune-checkpoint inhibitors (CPI). In a study comparing T-cell function in patients with MGUS versus multiple myeloma, T cells from patients with multiple myeloma were unable to mount responses to tumor cells (16) . This was in contrast to T cells from patients with MGUS, which retained ex vivo antitumor activity (16) . Taken together, these observations indicate that T cells in multiple myeloma lose the ability to naturally control tumor progression (16) .
Several mechanisms for multiple myeloma-associated reductions in T-cell immunity/responsiveness have been proposed, including T-cell exhaustion, anergy, and/or senescence (17) . Reduced T-cell recognition of multiple myeloma may also be due to ineffective antigen processing/presentation in vivo by tumor cells or dendritic cells (DC) (18) (19) (20) . In one study, T cells from multiple myeloma tumor beds were found to elicit strong, multiple myeloma-specific cytolytic responses only after ex vivo stimulation with autologous DCs (21) . This suggests that endogenous T cells from patients with multiple myeloma can be activated to mount an antitumor response (21, 22) .
T-cell-Dependent Immuno-oncology Therapies in Multiple Myeloma
Understanding the mechanisms affecting T-cell immunity provides opportunities for therapy development. Here, we discuss developments in T-cell-dependent immuno-oncology therapies in multiple myeloma, including vaccines, CPIs, cellular therapies, and bispecific antibodies (bsAb)/antibody constructs. MAbs (e.g., daratumumab, elotuzumab, and antibody drug conjugates) and NK cell-based therapies in multiple myeloma have been recently reviewed (23, 24) and are beyond the scope of this review.
Vaccines
Anticancer vaccination aims to re-educate host immunity, stimulate/expand tumor-specific effector cells, and generate long-term memory (25, 26) . Vaccine efficacy and response time depend on effector cell function/proliferation and tumor burden (26) . Current anti-multiple myeloma vaccine strategies are targeting disease stages with lower tumor burden and/or immunosuppression (26) , including stem cell transplantation (SCT), precursor disease, and minimal residual disease (MRD) settings.
Recent anti-multiple myeloma vaccination approaches can be categorized into targeted antigen-and whole cell-based methodologies. Targeted antigen approaches include protein/peptide-based vac-cines that introduce tumor-associated antigens (TAA) to recruit native DCs for antigen processing/presentation and subsequent multiple myeloma-specific effector cell expansion (25) . In the peritransplantation setting, studies have explored vaccines targeting MAGE-A3, hTERT, or survivin in conjunction with vaccine-primed autologous lymphocyte infusion (27) (28) (29) . In SMM, a multipeptide vaccine targeting XBP1, CD138, and SLAMF7/CS1 (PVX-410) demonstrated singleagent immunogenicity that was enhanced with lenalidomide (30) . Ongoing studies are evaluating PVX-410 with other combinations in precursor disease.
To elicit broader anti-multiple myeloma immune responses, whole cell-based methodologies present a greater spectrum of TAAs in the context of DC-mediated costimulation (26) . An allogeneic vaccine deepened responses in one study: 3 of 4 patients with stable nearcomplete response (nCR) achieved complete response (CR) postvaccination (31) . In the autologous SCT (autoSCT) setting, an autologous DC/multiple myeloma hybridoma vaccine converted 24% of patients with partial response posttransplantation to CR/nCR postvaccination (32) . These results have led to ongoing phase II trials; studies testing vaccines targeting neoantigens are also emerging ( Fig. 2 ; Supplementary Table S1 ).
CPIs
The overactivation of inhibitory immune-checkpoint pathways [e.g., programmed cell death protein-1 (PD-1)/PD-ligand 1 (PD-L1) pathway] in cancer suppresses immunosurveillance (33) . CPIs that block these pathways enable tumor-reactive cells to mount immune responses (34) . CPIs have been effective in other malignancies (33, 35) , but their role in multiple myeloma remains unclear. Although nivolumab (anti-PD-1) had no significant single-agent activity in relapsed/refractory multiple myeloma (36) , two phase I/II studies using pembrolizumab (anti-PD-1) plus an IMiD and dexamethasone showed overall response rates (ORR) of 44% to 60% in patients with relapsed/refractory multiple myeloma (37, 38) .
However, in two phase III trials, patients with newly diagnosed multiple myeloma (NDMM) or relapsed/refractory multiple myeloma Changes in the T-cell repertoire during multiple myeloma disease progression. Bars with gradients denote changes in T-cell populations (9, 10, 13-17, 21, 85, 86) ; darker shades correspond to increased levels, whereas lighter shades correspond to reduced levels. BM, bone marrow; MGUS, monoclonal gammopathy of undetermined significance; NKT, natural killer T cell; PB, peripheral blood; SMM, smoldering multiple myeloma; Th, T helper cell. a Referenced studies do not include BM and PB of age-matched healthy donors (16, 21) . b Referenced studies do not include PB of patients with precursor disease or direct comparisons of BM Th17 frequency between age-matched healthy donors and patients with precursor disease (14, 15) .
who received pembrolizumab plus an IMiD and dexamethasone experienced greater rates of grade !3 immune-related adverse events (AE)/death compared with standard of care, without appreciable improvements in response (39, 40) . These safety concerns led to the suspension of both trials by the Food and Drug Administration (FDA); several other CPI/IMiD combination studies were halted (34) . The lack of CPI success in multiple myeloma remains unexplained; one hypothesis is reduced CPI response due to T-cell senescence (17) .
Ongoing efforts are evaluating PD-1/PD-L1 inhibitors with other mAbs, vaccines, and as consolidation therapy post-SCT (Supplementary Table S2 ). Other CPI targets (e.g., Lag-3, Tim-3, and TIGIT) have demonstrated preclinical efficacy in multiple myeloma models (41, 42) .
Given their potential for enhancing T-cell activation, agonistic antibodies targeting costimulatory receptors (e.g., CD137/4-1BB, OX40) are also under investigation (41) . Figure 2 .
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AACRJournals.org Clin Cancer Res; 26(7) April 1, 2020 domain, to bypass major histocompatibility complex (MHC)-dependent binding to TAAs, and intracellular signaling domains for T-cell activation/costimulation (43) . T-cell activation is initiated following immune synapse (IS) formation, which facilitates lytic granulemediated apoptosis of the target cell. Notably, the CAR T cellinduced IS differs in composition and subdomain arrangement compared with the classic TCR-induced IS (e.g., smaller/patchy actin ring, disorganized distribution of signaling molecule Lck, and lack of an adhesion ring); these differences were associated with faster destruction and detachment from target cells (44) . Anti-CD19 CAR T cells demonstrated significant clinical activity in patients with relapsed/refractory B-cell leukemia and lymphoma (45) (46) (47) . In multiple myeloma, CAR T-cell therapies targeting B-cell maturation antigen (BCMA) have shown the most promise to date (48) (49) (50) . BCMA demonstrates relatively restricted expression on plasma cells and is expressed on multiple myeloma cells of virtually all patients with varying intensity (49) . Preclinical studies have also demonstrated a role for BCMA in promoting multiple myeloma progression in vivo (51, 52) . Therefore, BCMA represents a rational anti-multiple myeloma target.
Early studies of BCMA-targeting CAR T-cell therapy in patients with refractory multiple myeloma (median 7-9.5 prior lines) reported ORRs of 64%-90% in patients treated at optimal doses (>10 8 CAR T cells), including induction of MRD-negative CRs (53) (54) (55) . Response durability and progression-free survival (PFS) have been more variable, but PFS was $11.8 months in the first 33 patients treated with the anti-BCMA CAR T-cell therapy bb2121 (53) . In another anti-BCMA CAR T-cell trial in less heavily pretreated patients (n ¼ 57, median 3 prior lines), ORR was 88% (68% CR), and median PFS was $15 months (56). Multiple anti-BCMA CAR T-cell trials have since opened (Tables 1 and 2), and preliminary findings have supported this initial activity. Longer follow-up is needed to determine response durability.
Current CAR T-cell manufacturing processes may impede prompt treatment of aggressive disease, and a significant proportion of leukopheresed patients (8%-14% in 2 recent trials; refs. 53 and 54) may never receive treatment due to rapid progression/clinical deterioration. Faster manufacturing protocols (57), allogeneic CAR T-cell products (58) , and/or earlier treatment may help overcome this limitation.
CAR T-cell-associated toxicities include target-specific and -nonspecific effects of immune activation, particularly cytokine release syndrome (CRS) and neurotoxicity (49) . Most anti-BCMA CAR T-cell studies in multiple myeloma have reported any-grade CRS rates >60%; rates of grade !3 CRS are variable, but have been up to 41% ( Table 1) . CRS can usually be abrogated with tocilizumab (anti-IL6R mAb). Neurotoxicity has been reported in up to 42% of patients (53), comparable with anti-CD19 CAR T cells; neurotoxicity has usually been self-limited and/or responded to steroids, though severe cases have been observed (53) (54) (55) .
Another important consideration for CAR T cells is lymphodepletion, a strategy used to deplete immunosuppressive cell populations and improve CAR T-cell proliferation and engraftment (59) . Lymphodepletion has enhanced the clinical benefit of CAR T-cell therapy in hematologic malignancies (60, 61) , suggesting that preconditioning is an important procedure for this therapeutic class. In one multiple myeloma study, short-term CAR T-cell expansion was more consistently observed in patients who received cyclophosphamide lymphodepletion than those who did not (54) .
Other adoptive cellular therapies are also under investigation. Autologous Tg TCR T cells are ex vivo-modified to express TCRs targeting extracellular or intracellular TAAs, albeit with MHCrestricted recognition (49, 62) . Tg TCR T cells targeting NY-ESO-1 were well tolerated in patients with HLA A0201 þ multiple myeloma (n ¼ 20; median 3 prior lines) when infused (day 2) after autoSCT; nCR/CR was seen in 14 of 20 (70%) patients, with a median PFS of 19.1 months (63) . A trial investigating NY-ESO-1 Tg TCR T cells lacking PD-1 administered without autoSCT is ongoing (NCT03399448). MILs harbor a greater proportion of activated, memory, multiple myeloma-specific T cells, and show greater ex vivo anti-multiple myeloma activity than peripheral blood lymphocytes (64) . In a phase I study, 22 patients with multiple myeloma (45% relapsed/refractory) received ex vivo-activated MIL (day 3) following autoSCT. Anti-multiple myeloma immune responses were significantly greater post-MIL infusion, and stronger immune activity correlated with deeper clinical responses (65) . ORR was 54%; in patients who achieved !90% and <90% reduction in disease burden, median PFS was 25.1 months and 11.8 months, respectively (65) . These results led to an ongoing phase II trial of MILs þ autoSCT (NCT01045460).
Bispecific Antibodies (bsAb)/Antibody Constructs
BsAbs/antibody constructs are engineered to simultaneously engage endogenous T cells and tumor cells via binding to CD3 and any extracellular TAA, respectively, activating the T cells to attack the tumor cells (66) . Advantages of bsAbs/antibody constructs include their ability to act independently of MHC/TCR specificity, costimulation, or peptide antigen presentation (67, 68) . Furthermore, these molecules do not require ex vivo T-cell manipulation (68), enabling immediate treatment initiation. Upon T-cell recruitment to a cancer cell, an IS forms that is virtually indistinguishable from the endogenous TCR-induced synapse (69) . IS formation induces the release of cytotoxic granules (e.g., perforin, granzymes) from the activated T cell, leading to tumor cell death. BsAbs/antibody constructs promote serial lysis and sustained T-cell activation, leading to polyclonal expansion of memory T cells (67, 70, 71) . The bsAb/antibody construct with the most clinical experience to date is the BiTE (bispecific T-cell engager) platform, which utilizes 2 single-chain variable domains connected by a short linker. The resulting protein has a short serum half-life, requiring continuous infusion. An example is blinatumomab, which targets CD3 and CD19. Blinatumomab demonstrated clinical activity in relapsed/refractory acute lymphoblastic leukemia (ALL; refs. 72, 73), leading to FDA approval in 2014. Toxicities include CRS and neurotoxicity, which usually improve with infusion cessation and, if needed, steroid and/or tocilizumab administration.
The first bsAb/antibody construct with available clinical data in multiple myeloma is the BCMA-targeting molecule AMG 420 ( Table 1 ). In a phase I dose-escalation study, patients with relapsed and/or refractory multiple myeloma (n ¼ 42; median 4 prior lines) were continuously infused with AMG 420 (0.2-800 mg/d; 4 weeks on/ 2 weeks off, up to 10 cycles; ref. 74 ). The most frequently reported serious AEs were infections (31%) and peripheral polyneuropathy (5%); CRS was observed in 38% of patients, mostly grade 1. The 800 mg/d dose was not tolerable in this study (2/3 patients experienced dose-limiting toxicities). At 400 mg/d (recommended dose for this study), 70% (7/10) of patients responded, including 5 MRDnegative stringent CRs. The median time to response was 1 month, Three patients with extramedullary disease were evaluated as partial response at day 28 but were excluded from the efficacy analysis. c MM patient values only.
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Clin Cancer Res; 26(7) April 1, 2020 CLINICAL CANCER RESEARCH and response duration is 5.6 to 10.4 months to date, with several ongoing at the time of presentation (74) . A phase Ib/II multicenter study has recently opened (NCT03836053). Several additional T-cell redirecting bsAb/antibody constructs have entered clinical trials, with no efficacy data yet available ( Fig. 2 and Table 2 ). Other BCMA-targeting investigational constructs include PF-06863135, AMG 701, JNJ-64007957, CC-93269/EM901, REGN-5458, and TNB-383B. BsAbs/antibody constructs targeting alternative multiple myeloma surface antigens include GBR-1342 and AMG 424 (anti-CD38), BFCR4350A (anti-FcRH5), and JNJ-64407654 (anti-GPRC5D). Each product differs in construction, binding sites, and affinities; however, most contain an Fc domain, creating an "IgG-like" molecule. Advantages of this type of molecule include a longer half-life (allowing for intermittent dosing; ref. 75) , retention (in some constructs) of Fc-mediated effector functions (76) , and potential subcutaneous administration. A theoretical disadvantage of this approach is more prolonged toxicity, but preliminary results from a phase I study (n ¼ 5) of the IgG-like, BCMA-specific bsAb/antibody construct PF-06863135 showed a promising safety profile (77) . Comparisons of safety/efficacy profiles with canonical BiTE molecules may be available within the next year. Research investigating trispecific antibodies (e.g., HPN217; ref. 78) is also emerging.
Challenges and Future Strategies of T-cell-Dependent Immuno-oncology Therapy
Although the immuno-oncology field has evolved rapidly and shown promise in multiple myeloma, T-cell-dependent immunooncology therapies face several challenges (Fig. 3) . With the large number of available multiple myeloma therapies and many promising immuno-oncology approaches under investigation, determining the optimal treatment setting (considering disease stage, phenotype, and kinetics) and sequence within the current multiple myeloma treatment paradigm is complex.
Several classes of immuno-oncology agents have shown promise and recaptured immune responses in relapsed and/or refractory multiple myeloma, supporting their role in this setting. However, efficacy may be enhanced in a less dysregulated immune microenvironment, providing a rationale for evaluating these therapies earlier in the disease course. For example, in heavily pretreated patients with multiple myeloma, BCMA CAR T-cell expansion and response were associated with a preserved CD4:CD8 ratio and an increased frequency of CD45RO À CD27 þ CD8 þ T cells, reflective of na€ ve and stem cell memory T cells, prior to T-cell collection/ manufacturing (54, 79) . This phenotype was present more frequently in multiple myeloma patients with T cells harvested earlier in the disease course (80) . Similarly, although bsAbs/antibody constructs have advantageous features that may help overcome immuneescape mechanisms in multiple myeloma, their activity may still be affected by endogenous T-cell quality (81) . Therefore, bsAb/ antibody construct efficacy may also be greater in less immunosuppressed patients. Further studies will help determine whether Tcell phenotype and/or function remain predictive of clinical outcomes with other CAR T-cell and bsAb/antibody constructs in multiple myeloma. The data thus far suggest that efficacy may be improved when the endogenous T-cell repertoire is in a healthier state (48) . Vaccine, CPI, and CAR T-cell therapies are currently being evaluated as consolidation of first remission in NDMM, and vaccines are being studied even in MGUS/SMM (Fig. 2) . BsAbs/ antibody constructs may also be applicable across the multiple myeloma disease continuum.
The posttransplantation consolidation setting provides another opportunity for immuno-oncology therapy, as immunosuppressive cell numbers drop following SCT (34) . Furthermore, as myeloablative therapy frees the BM niche, immuno-oncology treatment may repopulate the niche with tumor-reactive cells. Vaccines and CPIs are under investigation in the transplantation setting (Fig. 2) ; CAR T-cell and bsAb/antibody construct efficacy may also be enhanced in this setting. In a pilot study, tandem autoSCT and combined anti-CD19/BCMA CAR T-cell administration for highrisk NDMM patients resulted in dramatic CAR T-cell expansion, possibly due to deeper and more prolonged lymphopenia post-SCT, with promising efficacy and safety (82) . Notably, the T-cell population utilized by CAR T cells and bsAbs/antibody constructs in this setting would likely differ: CAR T cells would likely be manufactured from T cells harvested before transplantation, whereas bsAbs/antibody constructs would engage T cells established posttransplantation.
Finally, determining the optimal treatment sequence, patient selection (high-risk patients, frail patients, etc.), potential for combination with current standard of care and/or other immunooncology therapies, and overall cost of these therapies will be important areas of future work and ongoing clinical trials (Fig. 2) . Several additional factors require further investigation. First, it will be important to understand how immuno-oncology therapies used at relapse may be affected by prior exposure to treatments with immunomodulatory actions, including IMiDs (may enhance effector cell cytotoxic activity), PIs (capable of inducing immunogenic cell death; activating DCs; ref. 6) , and anti-CD38 mAbs (may deplete immunosuppressive cell populations; expand helper and cytotoxic T cells; ref. 83 ). The first-line use of daratumumab will likely increase, with a consequent need for effective therapies for patients with daratumumab-refractory disease. Second, investigating the potential cross-resistance between immuno-oncology agents targeting the same antigen is warranted. Finally, retreatment at relapse with the same immuno-oncology product used at diagnosis may be feasible (84) , depending on several factors (e.g., response to initial therapy, target antigen loss), and merits further study in multiple myeloma.
Conclusion
Progressive immune dysfunction is a hallmark of the multiple myeloma disease course. This has led to the development of numerous treatment strategies aimed at overcoming the immunosuppressive tumor microenvironment and stimulating the host immune system to elicit an antitumor response. The promising preliminary efficacy of T-cell-dependent immuno-oncology therapies (e.g., CAR T cells, bsAbs/antibody constructs) has generated excitement, particularly in heavily pretreated multiple myeloma patients with limited treatment options. As immuno-oncology innovations continue to demonstrate activity, opportunities remain to improve clinical benefit, tolerability, and access. Advances in our understanding of the interactions between the immune system and the multiple myeloma disease continuum will be critical in guiding future investigations to optimize immune system redirection and provide the greatest outcomes for patients with multiple myeloma. • Gamma-secretase inhibition for BCMA (e.g., NCT03502577)
• Preferential transduction of T CM and T SCM cell Comparison of CAR T-cell and bsAb/antibody construct immuno-oncology approaches in multiple myeloma. Similarities and differences in structure and manufacturing (43, 49, 68) , as well as challenges and current strategies for improvement (75, 82, (87) (88) (89) (90) (91) (92) . BCMA, B-cell maturation antigen; BiTE, bispecific T-cell engager; bsAb, bispecific antibody; CAR, chimeric antigen receptor; CM, central memory; CRS, cytokine release syndrome; HAMA, human anti-mouse antibody; mAb, monoclonal antibody; MIL, marrow-infiltrating lymphocyte; scFV, single-chain variable fragment; SCM, stem cell memory; TAA, tumor-associated antigen; TCR, T-cell receptor.
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